Prelude Capital Management’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$112K Sell
12,229
-3,138
-20% -$28.6K 0.01% 892
2025
Q1
$122K Sell
15,367
-16,833
-52% -$134K 0.01% 932
2024
Q4
$175K Buy
32,200
+6,000
+23% +$32.6K 0.01% 894
2024
Q3
$189K Buy
26,200
+6,567
+33% +$47.4K 0.01% 974
2024
Q2
$213K Buy
19,633
+1,440
+8% +$15.6K 0.01% 881
2024
Q1
$341K Sell
18,193
-3,786
-17% -$71K 0.02% 749
2023
Q4
$476K Buy
21,979
+3,937
+22% +$85.3K 0.03% 465
2023
Q3
$371K Buy
18,042
+9,025
+100% +$186K 0.02% 474
2023
Q2
$424K Sell
9,017
-4,983
-36% -$234K 0.03% 453
2023
Q1
$587K Buy
14,000
+1,978
+16% +$83K 0.04% 363
2022
Q4
$459K Sell
12,022
-13,084
-52% -$499K 0.02% 532
2022
Q3
$983K Buy
25,106
+133
+0.5% +$5.21K 0.04% 428
2022
Q2
$807K Buy
24,973
+14,976
+150% +$484K 0.02% 498
2022
Q1
$331K Buy
+9,997
New +$331K 0.01% 819
2021
Q3
Sell
-4,812
Closed -$273K 1665
2021
Q2
$273K Buy
+4,812
New +$273K 0.01% 997
2021
Q1
Sell
-7,574
Closed -$655K 1343
2020
Q4
$655K Buy
7,574
+1,866
+33% +$161K 0.02% 296
2020
Q3
$349K Sell
5,708
-2,794
-33% -$171K 0.02% 353
2020
Q2
$354K Buy
+8,502
New +$354K 0.02% 368
2020
Q1
Sell
-8,381
Closed -$605K 1465
2019
Q4
$605K Buy
8,381
+2,870
+52% +$207K 0.02% 282
2019
Q3
$773K Buy
5,511
+2,519
+84% +$353K 0.03% 217
2019
Q2
$548K Buy
+2,992
New +$548K 0.03% 269
2018
Q4
Sell
-1,818
Closed -$257K 1702
2018
Q3
$257K Sell
1,818
-1,231
-40% -$174K 0.01% 483
2018
Q2
$477K Sell
3,049
-2
-0.1% -$313 0.03% 426
2018
Q1
$491K Sell
3,051
-769
-20% -$124K 0.04% 387
2017
Q4
$629K Sell
3,820
-60
-2% -$9.88K 0.05% 315
2017
Q3
$242K Sell
3,880
-1,180
-23% -$73.6K 0.02% 524
2017
Q2
$403K Hold
5,060
0.04% 332
2017
Q1
$360K Buy
5,060
+159
+3% +$11.3K 0.03% 344
2016
Q4
$250K Buy
+4,901
New +$250K 0.03% 459